Powys County, Wales (21 February, 2012) Hay-on-Wye based pharmaceutical packaging and clinical trials services specialist Brecon Pharmaceuticals announces the expansion of its storage and distribution capacity, with investment in a state-of-the-art, purpose-built facility in Pontypridd. The investment reflects Brecon Pharmaceuticals’ on-going commitment to continued excellence and to local economic growth.
Founded in 1980 and with premises based in the spectacular Wye Valley, Brecon Pharmaceuticals is one of the leading outsource service providers in the global pharmaceutical industry.
During the past 12 months, the company has defied the economic climate and continued to introduce the latest technologies and market-leading packaging solutions, attracting major contract wins. At the same time, Brecon has maintained its recruitment drive, which has seen an increase in its staff of over 10% in the same period.
Peter Belden, Managing Director comments: “The recent expansion reflects our commitment to innovation and quality through continuous investment in our people, facilities and equipment – a policy that has been rewarded with an almost tenfold increase in sales since 2002.”
Belden continues “The new site in Wales brings new opportunities for the area and the company is committed to recruiting local people from diverse background and providing them with training and expertise that are invaluable to personal development and to the development of the local economy.”
Brecon Pharmaceuticals and its sister company in the United States, Anderson Packaging, supports clients from the earliest stage of R&D through clinical trial and filing and on to commercialisation, packaging and supply. It works with a wide range of clients from small, ‘virtual’ companies through to the biggest global pharmaceutical organisations.
ENDS
Notes to Editor
About Brecon Pharmaceuticals
Founded in 1980, Brecon Pharmaceuticals is acknowledged as one of the leading outsourced-service providers in the global pharmaceutical industry. With unparalleled expertise in clinical trials supplies management and packing of solid dose forms into blisters, strips, wallets, bottles or sachets, backed by full in-house analytical services, Brecon is the preferred partner of the global pharmaceutical community. The company’s purpose-built facilities in Hay-on-Wye, Herefordshire, are the best-equipped and most modern in the UK.
Since 2006 Brecon has been a business of AmerisourceBergen Corporation. AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With $80 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. AmerisourceBergen is ranked #27 on the Fortune 500 list.
Brecon works closely with its AmerisourceBergen sister company Anderson Packaging (Rockford, IL) to deliver harmonised services in Europe, the Americas and beyond.
For further information please visit www.breconpharm.com
For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: brecon@scottpr.com
Tuesday 21 February 2012
PRECOS Appoints Dr Martin Page as Scientific Consultant
NOTTINGHAM, UK, 20th February 2012 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, announces the appointment of Dr Martin Page as scientific consultant. Dr Page brings over 28 years’ experience of oncology R&D leadership gained from the pharmaceutical and biotechnology sectors across UK, Europe and USA. His extensive therapeutic experience and industry knowledge will contribute to the company’s expert delivery of innovative patient relevant models for oncology research.
Dr Page has led multiple teams discovering novel targeted small molecule and MAb anti-cancer agents which have entered clinical trials. Prior to this new role, he was Vice President, Head of Global Oncology Research for Johnson & Johnson Pharmaceuticals, responsible for laboratories in Belgium and USA.
Dr Neil Rotherham, chairman of the PRECOS board comments, “We are delighted to welcome Martin to our team of visionary scientists. Dr Page’s expertise will be invaluable in PRECOS’ continued success as a trusted and preferred partner for some of the world’s leading oncology research companies.”
Previously Dr Page has held senior positions as Oncology Therapeutic Area Head/Europe for Glaxo-Wellcome and Senior Director positions in the biotechnology companies Oxford GlycoSciences and Oncogene Sciences Inc. He will support PRECOS to continue to advance its world-leading work in the evaluation of potential therapeutic agents, regimens and basic research into deriving the most relevant in vitro and in vivo screening models.
“I am extremely excited to work alongside the PRECOS team of expert scientists who are leading the way in providing robust models to enable testing of the next generation of oncology drug candidates,” said Dr Page. “PRECOS translates its expertise in cancer drug development to enable the development of medicines with real patient benefits and my appointment reinforces the ambition and potential of PRECOS to contribute in a significant way to the growing cancer therapy market.”
Dr Martin Page will be attending the AACR conference, Chicago, March 31st - April 4th 2012, booth #4306, where PRECOS will be showcasing several new platforms for pre-clinical oncology research. To arrange a meeting please contact PRECOS on +44 (0)870 166 6234, email enquiries@precos.co.uk or visit www.precos.co.uk for further information.
About PRECOS Ltd
PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade. For further information: www.precos.co.uk
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: precos@scottpr.com
Dr Page has led multiple teams discovering novel targeted small molecule and MAb anti-cancer agents which have entered clinical trials. Prior to this new role, he was Vice President, Head of Global Oncology Research for Johnson & Johnson Pharmaceuticals, responsible for laboratories in Belgium and USA.
Dr Neil Rotherham, chairman of the PRECOS board comments, “We are delighted to welcome Martin to our team of visionary scientists. Dr Page’s expertise will be invaluable in PRECOS’ continued success as a trusted and preferred partner for some of the world’s leading oncology research companies.”
Previously Dr Page has held senior positions as Oncology Therapeutic Area Head/Europe for Glaxo-Wellcome and Senior Director positions in the biotechnology companies Oxford GlycoSciences and Oncogene Sciences Inc. He will support PRECOS to continue to advance its world-leading work in the evaluation of potential therapeutic agents, regimens and basic research into deriving the most relevant in vitro and in vivo screening models.
“I am extremely excited to work alongside the PRECOS team of expert scientists who are leading the way in providing robust models to enable testing of the next generation of oncology drug candidates,” said Dr Page. “PRECOS translates its expertise in cancer drug development to enable the development of medicines with real patient benefits and my appointment reinforces the ambition and potential of PRECOS to contribute in a significant way to the growing cancer therapy market.”
Dr Martin Page will be attending the AACR conference, Chicago, March 31st - April 4th 2012, booth #4306, where PRECOS will be showcasing several new platforms for pre-clinical oncology research. To arrange a meeting please contact PRECOS on +44 (0)870 166 6234, email enquiries@precos.co.uk or visit www.precos.co.uk for further information.
About PRECOS Ltd
PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade. For further information: www.precos.co.uk
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: precos@scottpr.com
HCL snaps up Yorkshire Trust win
The Mid Yorkshire Hospitals NHS Trust has awarded leading locum doctor provider HCL Thames Medics the contract to be their tier one sole supplier of staff.
Mid Yorkshire Hospitals, an acute hospital Trust, primarily serves the communities of Wakefield District and North Kirklees, which makes up more than half a million people.
HCL Thames Medics Managing Director, Liz Fendyke, negotiated the deal which looks set to demonstrate HCL’s recognition of the financial constraints under which the NHS are currently operating.
“We are thrilled to have secured this contract at the Mid Yorkshire Hospitals, and we see it as in excellent opportunity to showcase HCL’s capacity as a volume supplier to the NHS,” Ms Fendyke said.
Mid Yorkshire Hospitals currently serves over 550 people per day in their emergency departments.
“Our commitment to reducing the agency spend of our clients will ensure we continue to offer the Mid Yorkshire Hospitals Trust low-cost volume solutions, compliance assurance and an impeccable service.”
HCL, as a preferred Government Procurement Service (GPS) framework-approved agency to a large number of Trusts and procurement hubs, currently holds exclusive contracts at national, regional and Trust level at some of the most prestigious hospitals across the UK.
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540. E-mail healthcarelocums@scottpr.com.
About HCL plc
HCL plc, headquartered in London, was formed in 2003 and is a leading provider of staffing solutions in the health and social care sectors within our chosen markets. HCL supply over 2,000 temporary and permanent Doctors, Allied Health Professionals (AHP), qualified social workers and administration & clerical staff to public and private sectors. We are an international company with offices in UK and Australia and recruitment drives in Europe. Please visit our website at www.healthcarelocums.com
For UK updates or job information, follow us on Twitter: @HCLplc
For Australian updates or job information, follow us on Twitter: @HealthcareAus
Mid Yorkshire Hospitals, an acute hospital Trust, primarily serves the communities of Wakefield District and North Kirklees, which makes up more than half a million people.
HCL Thames Medics Managing Director, Liz Fendyke, negotiated the deal which looks set to demonstrate HCL’s recognition of the financial constraints under which the NHS are currently operating.
“We are thrilled to have secured this contract at the Mid Yorkshire Hospitals, and we see it as in excellent opportunity to showcase HCL’s capacity as a volume supplier to the NHS,” Ms Fendyke said.
Mid Yorkshire Hospitals currently serves over 550 people per day in their emergency departments.
“Our commitment to reducing the agency spend of our clients will ensure we continue to offer the Mid Yorkshire Hospitals Trust low-cost volume solutions, compliance assurance and an impeccable service.”
HCL, as a preferred Government Procurement Service (GPS) framework-approved agency to a large number of Trusts and procurement hubs, currently holds exclusive contracts at national, regional and Trust level at some of the most prestigious hospitals across the UK.
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540. E-mail healthcarelocums@scottpr.com.
About HCL plc
HCL plc, headquartered in London, was formed in 2003 and is a leading provider of staffing solutions in the health and social care sectors within our chosen markets. HCL supply over 2,000 temporary and permanent Doctors, Allied Health Professionals (AHP), qualified social workers and administration & clerical staff to public and private sectors. We are an international company with offices in UK and Australia and recruitment drives in Europe. Please visit our website at www.healthcarelocums.com
For UK updates or job information, follow us on Twitter: @HCLplc
For Australian updates or job information, follow us on Twitter: @HealthcareAus
The Scott Partnership Appoints Former Golley Slater Managing Director in New General Manager Role
Cheshire, UK (21 February 2012)- The Scott Partnership, a leading global business-to-business PR and marketing communications consultancy based in Cheshire, UK, is delighted to announce the appointment of Sion Ashley-Jones as Director and General Manager. A strong and continuous history of growth in The Scott Partnership has led to this appointment in which Sion will lead the expansion of the team.
As a former managing director of UK full service marketing communications agency, Golley Slater, Sion brings with him a wealth of experience in PR, marketing, branding, digital media and creative advertising in both the B2B and consumer sectors. Sion’s skills complement The Scott Partnership’s mission to continue growing their brand into becoming a full service communications agency, specializing in a number of different fields. Before joining The Scott Partnership, Sion directed communications for a variety of international and household clients including: The Army, Lloyds TSB Insurance, BMW, Mitsubishi Motors, Welsh Rugby Union, NatWest, VW and Konica Minolta. His contribution to the industry has been recognized with a breadth of prestigious awards including Silver and Bronze at the International Kinsale Shark Awards, The Cannes Gold Lion and a Silver British Television Advertising Award.
Kath Darlington, CEO of The Scott Partnership comments, “Sion is a natural choice for our rapidly growing team, his experience of providing full marketing consultancy for a broad range of international clients complements our increasing position as an integrated partner for global clients. The Scott Partnership is moving from its niche specialism into becoming a global player, and Sion joins us at a key time to make a positive impact on our future.”
Sion Ashley-Jones comments, “The Scott Partnership is positioned in the heart of the creative communications industry and I am looking forward to being an integral part of creating a new and innovative agency model. Times have changed and The Scott Partnership embraces change. Our agency offerings will now evolve alongside our clients’ requirements and we will continue to strive to excite and engage on every brief that comes through our door.”
The appointment is another step in The Scott Partnership’s continued global growth strategy. It follows the recent acquisitions of life science agencies Kapler Communications Ltd and Phoenix Marcom Communications Ltd, as well as the launch of a new corporate communications practice.
-Ends-
The Scott Partnership was founded in 1996 in the UK and over the past 15 years has become one of the leading B2B communication consultancies in Europe, with expertise in life science, healthcare, chemical and materials, security, packaging, automation and analytical instruments. In the past two years, it has accelerated its pace of expansion with newly opened offices in both Shanghai and Boston.
For more information on The Scott Partnership, please call +44 (0)1477 539 539. Alternatively e-mail business@scottpr.com or visit www.scottpr.com.
As a former managing director of UK full service marketing communications agency, Golley Slater, Sion brings with him a wealth of experience in PR, marketing, branding, digital media and creative advertising in both the B2B and consumer sectors. Sion’s skills complement The Scott Partnership’s mission to continue growing their brand into becoming a full service communications agency, specializing in a number of different fields. Before joining The Scott Partnership, Sion directed communications for a variety of international and household clients including: The Army, Lloyds TSB Insurance, BMW, Mitsubishi Motors, Welsh Rugby Union, NatWest, VW and Konica Minolta. His contribution to the industry has been recognized with a breadth of prestigious awards including Silver and Bronze at the International Kinsale Shark Awards, The Cannes Gold Lion and a Silver British Television Advertising Award.
Kath Darlington, CEO of The Scott Partnership comments, “Sion is a natural choice for our rapidly growing team, his experience of providing full marketing consultancy for a broad range of international clients complements our increasing position as an integrated partner for global clients. The Scott Partnership is moving from its niche specialism into becoming a global player, and Sion joins us at a key time to make a positive impact on our future.”
Sion Ashley-Jones comments, “The Scott Partnership is positioned in the heart of the creative communications industry and I am looking forward to being an integral part of creating a new and innovative agency model. Times have changed and The Scott Partnership embraces change. Our agency offerings will now evolve alongside our clients’ requirements and we will continue to strive to excite and engage on every brief that comes through our door.”
The appointment is another step in The Scott Partnership’s continued global growth strategy. It follows the recent acquisitions of life science agencies Kapler Communications Ltd and Phoenix Marcom Communications Ltd, as well as the launch of a new corporate communications practice.
-Ends-
The Scott Partnership was founded in 1996 in the UK and over the past 15 years has become one of the leading B2B communication consultancies in Europe, with expertise in life science, healthcare, chemical and materials, security, packaging, automation and analytical instruments. In the past two years, it has accelerated its pace of expansion with newly opened offices in both Shanghai and Boston.
For more information on The Scott Partnership, please call +44 (0)1477 539 539. Alternatively e-mail business@scottpr.com or visit www.scottpr.com.
Wednesday 15 February 2012
ERT Launches New Website to Support Significant Commercial Growth
PHILADELPHIA, PA, 15 January- ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announced today the launch of a new corporate website to further elevate its market and thought leadership position. Complementing the company’s commercial growth in the last 18 months, web traffic to ERT’s website increased by 41% from June 2010 to October 2011, as visitors sought further detailed information about ERT’s comprehensive range of Cardiac Safety, Respiratory and ePRO solutions. To access the new website, visit www.ert.com.
The newly created website has been designed to reflect ERT’s position as a company offering unrivalled processes and scientific expertise to collect, analyze and report on clinical data. This is done in order to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products.
Created to provide a new online customer experience, the website provides enhanced content and improved navigation in order to give visitors a more comprehensive and in-depth understanding of ERT’s services and expertise in the health outcomes research field. Providing in depth information on ERT’s distinctive cardiac safety, respiratory and ePRO solutions, visitors are also able to learn about ERT’s clinical consulting services, which offer essential scientific and regulatory expertise in order to ensure quality trial data.
ERT’s commitment to making valuable resources available to patients and clients is fully realized by the new website. Leveraging the research of ERT’s experts and other thought leaders, the site offers a resource center that provides continually updated links to articles, white papers and webinars, in addition to up-to-date news stories. Featuring images and quotes from both junior and senior staff throughout the website, the new aesthetic enables users to see the human side of ERT and familiarize themselves with the experts and dedicated staff that support their research every day.
John Blakeley, Chief Commercial Officer, comments: “Our traditional markets are changing and we felt strongly that a new online presence was needed to better support our Sponsors and our CRO partners. This new site provides a valuable resource center that allows relevant stakeholders to access industry specific information and case studies.”
For further information on ERT and its technology and services, please email info@ERT.com, call +1 215 972 0420 or visit www.ERT.com
For further press information, please contact Fiona Robinson, the Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539 539, Fax +44 1477 539 540, Email ert@scottpr.com
About ERT
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivalled processes and scientific expertise to collect, analyse and report on clinical data to support the determination of health outcomes critical to the approval, labelling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO)and Outcomes Assessments for multiple modalities across all phases.
The newly created website has been designed to reflect ERT’s position as a company offering unrivalled processes and scientific expertise to collect, analyze and report on clinical data. This is done in order to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products.
Created to provide a new online customer experience, the website provides enhanced content and improved navigation in order to give visitors a more comprehensive and in-depth understanding of ERT’s services and expertise in the health outcomes research field. Providing in depth information on ERT’s distinctive cardiac safety, respiratory and ePRO solutions, visitors are also able to learn about ERT’s clinical consulting services, which offer essential scientific and regulatory expertise in order to ensure quality trial data.
ERT’s commitment to making valuable resources available to patients and clients is fully realized by the new website. Leveraging the research of ERT’s experts and other thought leaders, the site offers a resource center that provides continually updated links to articles, white papers and webinars, in addition to up-to-date news stories. Featuring images and quotes from both junior and senior staff throughout the website, the new aesthetic enables users to see the human side of ERT and familiarize themselves with the experts and dedicated staff that support their research every day.
John Blakeley, Chief Commercial Officer, comments: “Our traditional markets are changing and we felt strongly that a new online presence was needed to better support our Sponsors and our CRO partners. This new site provides a valuable resource center that allows relevant stakeholders to access industry specific information and case studies.”
For further information on ERT and its technology and services, please email info@ERT.com, call +1 215 972 0420 or visit www.ERT.com
For further press information, please contact Fiona Robinson, the Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539 539, Fax +44 1477 539 540, Email ert@scottpr.com
About ERT
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivalled processes and scientific expertise to collect, analyse and report on clinical data to support the determination of health outcomes critical to the approval, labelling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO)and Outcomes Assessments for multiple modalities across all phases.
Tuesday 14 February 2012
High-Throughput and High-Salt Measurements of Electrophoretic Mobility (Zeta Potential) with Wyatt Technology’s Möbius
(SANTA BARBARA, CALIFORNIA – February 14 2012) Wyatt Technology Corporation, the world leader in absolute macromolecular characterization instrumentation and software, today announces that it will be showcasing its innovative zeta potential instrument, the Möbius™, at PITTCON 2012. The Möbius has been developed to automate the measurement of the mobility and the hydrodynamic radius of precious protein samples, increasing throughput without modifying the species. Additionally, the instrument is designed to facilitate analyses in high-saline conditions, expanding the capability of the laboratory. Wyatt Technology will exhibit the Möbius on booth #2281 at PITTCON 2012, Orlando, FL, March 11- March 15, 2012.
Previously, conventional batch-mode zeta potential instrumentation has been incapable of automating macromolecular particle electrophoretic mobility for multiple samples. Used with an HPLC pump and an auto-sampler, the Möbius can overcome this challenge, presenting an automated and cost-effective instrument for protein analysis.
The Möbius offers a unique cell, designed as a closed system, which accepts sample delivery from an autosampler. Once the sample injection sequence is implemented and synchronized with a data acquisition schedule in its Dynamics™ software, automated measurement of multiple samples is enabled. This eliminates the need for manual injection, helping to increase laboratory productivity and maximize time-efficiency. With the additional possibility of a buffer injection in between samples further enhanced by a wash sequence, cross contamination of cells is minimized, helping to ensure data accuracy.
Aqueous samples with conductivities near or above the physiological saline condition have proven to be a challenge for zeta potential instruments. As electric current is passed through a conductive sample, electrochemical redox reactions bring about electrolysis on the surface of the electrodes. Inevitably, gas bubbles evolve to distort the driving electric field and compromise the light scattering signal used for the measurements.
Wyatt Technology has developed a system for use alongside the Möbius to overcome this challenge. Wyatt’s Atlas™ hardware pressurizes the cell, preventing bubble formation. As a result, previously problematic mobility analyses are now routine.
To learn more about Wyatt Technology’s Möbius and its capabilities, please visit booth #2281 at PITTCON 2012. Alternatively please visit www.wyatt.com or e-mail info@wyatt.com
####
About Wyatt
Based in Santa Barbara, California, Wyatt Technology is the world’s leading provider of instruments for absolute macromolecular characterization. With over 40 years’ experience developing multi-angle light scattering detectors, working with customers in the biotechnology, chemical, petrochemical, pharmaceutical, academic and government arenas, Wyatt prides itself on its entrepreneurial spirit, and the uniqueness of its offerings. The Company’s groundbreaking technology and uncompromising levels of customer care make Wyatt the global hallmark in its field. For more information, please visit www.wyatt.com
Previously, conventional batch-mode zeta potential instrumentation has been incapable of automating macromolecular particle electrophoretic mobility for multiple samples. Used with an HPLC pump and an auto-sampler, the Möbius can overcome this challenge, presenting an automated and cost-effective instrument for protein analysis.
The Möbius offers a unique cell, designed as a closed system, which accepts sample delivery from an autosampler. Once the sample injection sequence is implemented and synchronized with a data acquisition schedule in its Dynamics™ software, automated measurement of multiple samples is enabled. This eliminates the need for manual injection, helping to increase laboratory productivity and maximize time-efficiency. With the additional possibility of a buffer injection in between samples further enhanced by a wash sequence, cross contamination of cells is minimized, helping to ensure data accuracy.
Aqueous samples with conductivities near or above the physiological saline condition have proven to be a challenge for zeta potential instruments. As electric current is passed through a conductive sample, electrochemical redox reactions bring about electrolysis on the surface of the electrodes. Inevitably, gas bubbles evolve to distort the driving electric field and compromise the light scattering signal used for the measurements.
Wyatt Technology has developed a system for use alongside the Möbius to overcome this challenge. Wyatt’s Atlas™ hardware pressurizes the cell, preventing bubble formation. As a result, previously problematic mobility analyses are now routine.
To learn more about Wyatt Technology’s Möbius and its capabilities, please visit booth #2281 at PITTCON 2012. Alternatively please visit www.wyatt.com or e-mail info@wyatt.com
####
About Wyatt
Based in Santa Barbara, California, Wyatt Technology is the world’s leading provider of instruments for absolute macromolecular characterization. With over 40 years’ experience developing multi-angle light scattering detectors, working with customers in the biotechnology, chemical, petrochemical, pharmaceutical, academic and government arenas, Wyatt prides itself on its entrepreneurial spirit, and the uniqueness of its offerings. The Company’s groundbreaking technology and uncompromising levels of customer care make Wyatt the global hallmark in its field. For more information, please visit www.wyatt.com
Wednesday 8 February 2012
Greenphire Selected as a PACT Enterprise Award Finalist
King of Prussia, PA, 08 February, 2012 – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced that it has been chosen as one of three finalists for the Philadelphia Alliance for Capital and Technologies (PACT) Enterprise Award in the Technology Startup division. Selection for the award was based on Greenphire’s established success in delivering an innovative product to meet a significant market need, potential for significant growth, managerial ability and record of achieving success, and demonstration of success via significant business milestones such as raising capital and achieving revenue growth.
Greenphire and the other Enterprise Award finalist companies will be honored at the 19th Annual Enterprise Awards gala of 1,200 prominent business leaders on Thursday, May 3, 2012, at the Hilton Philadelphia City Line.
The Enterprise Award finalists were selected from among hundreds of Greater Philadelphia area technology and life sciences companies nominated by entrepreneurs, investors, bankers, journalists, and industry insiders. Past winners include Siemens Healthcare, BioClinica, Shire Pharmaceuticals, and other leaders in the pharmaceutical and clinical trials industry. The PACT board of independent judges conducted a rigorous two-month selection process to determine the finalists, and will continue to evaluate each finalist’s ongoing performance in order to choose the winners.
“This year the number of applicants and, more importantly, the quality of applicants was at an all-time high,” said Charles Robins, managing director at Fairmount Partners and lead judge for the Enterprise Awards. “We have been through an era where companies have had to live on less capital, and what’s happened is we have a new generation of companies and of entrepreneurs who are growing successfully. It sets a very optimistic base for our future, and all of the judges this year felt that all of the companies being honored as finalists are superb choices.”
Greenphire CEO Sam Whitaker expressed the company’s enthusiasm with the selection, saying “The Enterprise Award is the top regional recognition in our industry and we are thrilled to be considered for this prestigious honor. Greenphire has seen rapid expansion over the past year and this selection comes at the perfect time for us to continue establishing ourselves as the leaders in clinical payments both here in the greater Philadelphia region and across the clinical trials industry.”
A full list of this year’s Enterprise Award finalists and past winners can be found on the PACT website at http://pact.gpcc.com/
About Greenphire
Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.
For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.
Greenphire and the other Enterprise Award finalist companies will be honored at the 19th Annual Enterprise Awards gala of 1,200 prominent business leaders on Thursday, May 3, 2012, at the Hilton Philadelphia City Line.
The Enterprise Award finalists were selected from among hundreds of Greater Philadelphia area technology and life sciences companies nominated by entrepreneurs, investors, bankers, journalists, and industry insiders. Past winners include Siemens Healthcare, BioClinica, Shire Pharmaceuticals, and other leaders in the pharmaceutical and clinical trials industry. The PACT board of independent judges conducted a rigorous two-month selection process to determine the finalists, and will continue to evaluate each finalist’s ongoing performance in order to choose the winners.
“This year the number of applicants and, more importantly, the quality of applicants was at an all-time high,” said Charles Robins, managing director at Fairmount Partners and lead judge for the Enterprise Awards. “We have been through an era where companies have had to live on less capital, and what’s happened is we have a new generation of companies and of entrepreneurs who are growing successfully. It sets a very optimistic base for our future, and all of the judges this year felt that all of the companies being honored as finalists are superb choices.”
Greenphire CEO Sam Whitaker expressed the company’s enthusiasm with the selection, saying “The Enterprise Award is the top regional recognition in our industry and we are thrilled to be considered for this prestigious honor. Greenphire has seen rapid expansion over the past year and this selection comes at the perfect time for us to continue establishing ourselves as the leaders in clinical payments both here in the greater Philadelphia region and across the clinical trials industry.”
A full list of this year’s Enterprise Award finalists and past winners can be found on the PACT website at http://pact.gpcc.com/
About Greenphire
Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.
For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.
ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients
More than 150 patients with COPD will receive additional health care services to improve their health and lower the costs of long term care.
Program will test the benefits of remote monitoring services on a needy and growing population.
PHILADELPHIA, February, 2012- ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study. Conducted in collaboration with UCLA, the study is an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD). COPD is a leading and increasingly prevalent disease which, according to the World Health Organization, will become the world’s third most common cause of death by 2020.
COPD is a progressive and chronic inflammatory disease of airways that typically occurs in middle-aged and older patients. There is no cure for COPD, only therapies that manage the symptoms and seek to prevent acute and debilitating events such as pulmonary exacerbations. These exacerbations are an important cause of disability and further decrease in lung function, which typically require medical therapy at the home or in the hospital. Therefore, early identification and prevention of exacerbations are important, can improve the quality of life of the patients, and can delay or decrease the demand for expensive medical care.
To identify symptoms and concerns early, ERT and UCLA will be providing enhanced services to help the patients outside the physician’s office and beyond the normal process of care. The twelve month study is specifically designed to test whether remote health monitoring:
• Is feasible in patients with moderate-severe COPD
• Improves treatment adherence, symptoms, activity level and quality of life and enables early detection of COPD exacerbations, facilitating early interventions and reducing health related expenditures
The program will operate as a randomized study for patients over 40 years old receiving their care in the Los Angeles community. The program brings together home based spirometry, activity monitoring, adherence scoring, and self-reported symptom monitoring, all enabled through technology. On a daily basis in the patient’s home, enrollees will track their lung function using ERT’s SpiroPro® which will also record symptoms through questions of the CLEAR Sx Assessment instrument. Symptoms, such as breathlessness and cough, will be tracked on the SpiroPro using a novel series of screens adapted from previously reported instruments for the detection of exacerbations. The devices will also deliver the new CLEAR Rx and CLEAR Ex Assessment instruments to determine prescription adherence and perceived activity levels. Every day, enrollees will record their physical activity levels, such as the number of steps taken per day and total activity time, using a wearable accelerometer. All patient data will be securely uploaded to a web based data tracking site where trends in symptoms and concerns with patient status can be quickly identified and addressed through clinical care.
“The breadth of services is a truly unique and innovative design for respiratory care”, notes John Sory, ERT’s Chief Development Officer. “The combined efforts of UCLA and ERT will test new approaches and could well deliver a meaningful new approach for the benefit of patients where the burden of illness is high, the need for quick intervention apparent, and the demand for new forms of care increasingly acute.”
“COPD is a serious illness and early intervention can be critical in improving COPD patients’ quality of life. We welcome the opportunity to work with ERT in helping to remotely monitor patients on a daily basis in their own homes, which may help promptly identify health problems and ensure treatment adherence. Such monitoring may prove to be an important component in the future of healthcare delivery,” said Dr. Christopher Cooper, the study’s principal investigator and professor of medicine and physiology at the David Geffen School of Medicine at UCLA.
The first of over 200 patients are expected to be recruited starting in February, 2012 and patient outcomes will be reported in late 2013. Enrollees will have full physical exams upon enrollment and at the test conclusion. Throughout the period, the metrics to be tracked will include:
• Adoption rates of remote health monitoring
• Treatment adherence in terms of percentage of days prescribed treatment is taken
• Time to first COPD exacerbation as defined by standard criteria and number of exacerbations per year including the proportion of subjects experiencing one or more exacerbations
• Respiratory function values such as mean daily forced expiratory volume in one second (forced spirometry), inspiratory capacity (slow spirometry), and pulse oximetry (SPO2)
• Daily activity level and symptom scores
• Utilization information such as number of physician visits, emergency department visits, hospitalizations, number of days spent in hospital, and inferred health care costs
Dr. Jeffrey Litwin, President and CEO of ERT concluded, “We are excited to work with Dr Cooper and his colleagues at UCLA to help progress the adoption of remote healthcare monitoring and we look forward to learning and sharing the results of this important trial”.
For further information on ERT and its technology and services, please email info@ERT.com , call +1 215 972 0420 or visit www.ERT.com
For further press information, please contact Laura Browne, the Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539 539, Fax +44 1477 539 540, Email ert@scottpr.com
About UCLA
The David Geffen School of Medicine at UCLA is an internationally recognized leader in research, medical education and patient care. The school has more than 2,000 full-time faculty members, almost 1,300 residents, more than 750 medical students and roughly 400 Ph.D. candidates.
About ERT
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivalled processes and scientific expertise to collect, analyse and report on clinical data to support the determination of health outcomes critical to the approval, labelling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO)and Outcomes Assessments for multiple modalities across all phases.
Program will test the benefits of remote monitoring services on a needy and growing population.
PHILADELPHIA, February, 2012- ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study. Conducted in collaboration with UCLA, the study is an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD). COPD is a leading and increasingly prevalent disease which, according to the World Health Organization, will become the world’s third most common cause of death by 2020.
COPD is a progressive and chronic inflammatory disease of airways that typically occurs in middle-aged and older patients. There is no cure for COPD, only therapies that manage the symptoms and seek to prevent acute and debilitating events such as pulmonary exacerbations. These exacerbations are an important cause of disability and further decrease in lung function, which typically require medical therapy at the home or in the hospital. Therefore, early identification and prevention of exacerbations are important, can improve the quality of life of the patients, and can delay or decrease the demand for expensive medical care.
To identify symptoms and concerns early, ERT and UCLA will be providing enhanced services to help the patients outside the physician’s office and beyond the normal process of care. The twelve month study is specifically designed to test whether remote health monitoring:
• Is feasible in patients with moderate-severe COPD
• Improves treatment adherence, symptoms, activity level and quality of life and enables early detection of COPD exacerbations, facilitating early interventions and reducing health related expenditures
The program will operate as a randomized study for patients over 40 years old receiving their care in the Los Angeles community. The program brings together home based spirometry, activity monitoring, adherence scoring, and self-reported symptom monitoring, all enabled through technology. On a daily basis in the patient’s home, enrollees will track their lung function using ERT’s SpiroPro® which will also record symptoms through questions of the CLEAR Sx Assessment instrument. Symptoms, such as breathlessness and cough, will be tracked on the SpiroPro using a novel series of screens adapted from previously reported instruments for the detection of exacerbations. The devices will also deliver the new CLEAR Rx and CLEAR Ex Assessment instruments to determine prescription adherence and perceived activity levels. Every day, enrollees will record their physical activity levels, such as the number of steps taken per day and total activity time, using a wearable accelerometer. All patient data will be securely uploaded to a web based data tracking site where trends in symptoms and concerns with patient status can be quickly identified and addressed through clinical care.
“The breadth of services is a truly unique and innovative design for respiratory care”, notes John Sory, ERT’s Chief Development Officer. “The combined efforts of UCLA and ERT will test new approaches and could well deliver a meaningful new approach for the benefit of patients where the burden of illness is high, the need for quick intervention apparent, and the demand for new forms of care increasingly acute.”
“COPD is a serious illness and early intervention can be critical in improving COPD patients’ quality of life. We welcome the opportunity to work with ERT in helping to remotely monitor patients on a daily basis in their own homes, which may help promptly identify health problems and ensure treatment adherence. Such monitoring may prove to be an important component in the future of healthcare delivery,” said Dr. Christopher Cooper, the study’s principal investigator and professor of medicine and physiology at the David Geffen School of Medicine at UCLA.
The first of over 200 patients are expected to be recruited starting in February, 2012 and patient outcomes will be reported in late 2013. Enrollees will have full physical exams upon enrollment and at the test conclusion. Throughout the period, the metrics to be tracked will include:
• Adoption rates of remote health monitoring
• Treatment adherence in terms of percentage of days prescribed treatment is taken
• Time to first COPD exacerbation as defined by standard criteria and number of exacerbations per year including the proportion of subjects experiencing one or more exacerbations
• Respiratory function values such as mean daily forced expiratory volume in one second (forced spirometry), inspiratory capacity (slow spirometry), and pulse oximetry (SPO2)
• Daily activity level and symptom scores
• Utilization information such as number of physician visits, emergency department visits, hospitalizations, number of days spent in hospital, and inferred health care costs
Dr. Jeffrey Litwin, President and CEO of ERT concluded, “We are excited to work with Dr Cooper and his colleagues at UCLA to help progress the adoption of remote healthcare monitoring and we look forward to learning and sharing the results of this important trial”.
For further information on ERT and its technology and services, please email info@ERT.com , call +1 215 972 0420 or visit www.ERT.com
For further press information, please contact Laura Browne, the Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539 539, Fax +44 1477 539 540, Email ert@scottpr.com
About UCLA
The David Geffen School of Medicine at UCLA is an internationally recognized leader in research, medical education and patient care. The school has more than 2,000 full-time faculty members, almost 1,300 residents, more than 750 medical students and roughly 400 Ph.D. candidates.
About ERT
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with unrivalled processes and scientific expertise to collect, analyse and report on clinical data to support the determination of health outcomes critical to the approval, labelling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety and respiratory efficacy services and also provides electronic Patient Reported Outcomes (ePRO)and Outcomes Assessments for multiple modalities across all phases.
Thursday 2 February 2012
Prism Ideas and dMetrics Launch Pioneering Service Analysing Patient–Reported Action, Behaviours and Outcomes with Social Med
Cheshire, UK (February 2, 2012) Prism Ideas, the multi-national medical marketing and drug development consultants, today announced its collaboration with dMetrics, experts in identifying decisions made by millions of patients online, to launch a pioneering analysis service to evaluate patient healthcare outcomes reported within social media. Combining expertise in language analytics and healthcare, the two companies are interrogating social media to determine patient actions and insights, profiling patient needs, symptoms and response to treatment. The collaboration has already successfully completed projects in disease areas as diverse as allergic rhinitis (hayfever), multiple sclerosis and smoking cessation.
With increasing regulatory and healthcare provider interest in patient-reported outcomes, there is a growing need for technology that can measure and empirically substantiate the benefits to patients of new medical products. Unlike simple keyword-based market research systems, dMetrics’ MIT-founded technology harnesses Big Data to identify who makes decisions, what they decide and why those decisions are made regarding a product, connecting the multitude of voices into a compelling patient narrative. Together, Prism Ideas and dMetrics bring previously unavailable, unbiased insight and analysis of the collective action of many individual patients.
Fully compliant with industry standards of practice in both market research and pharmacovigilance, the reports can be used both for drug development planning and product assessment, providing information on disease epidemiology, symptoms and clinical outcomes, in addition to patient insight and value judgments. For sponsors requiring the rapid and efficient delivery of meaningful and longitudinal data, without the hurdle of long lead times or regulatory committees, this service is designed to provide the ideal solution and can be tailored to a sponsor’s specific requirements.
In a recent study, Prism Ideas and dMetrics designed a protocol and conducted an in silico study for Allergy Therapeutics to establish the level of symptom improvement considered to be meaningful by allergy sufferers. Previously there had been no clinical or regulatory consensus upon this subject, calling into question the value of some medications. Applying their experience and expertise, dMetrics and Prism Ideas were able to capture first person data reports relating to treatment intervention, symptoms impacted and/or outcomes-related sentiment. The results of the study were important, indicating that for many patients relief of even one hayfever symptom such as a blocked nose or sneezing was very important.
Dr Tom Holdich, Research and Development Director for Allergy Therapeutics explains: “Conventional clinical trials and patient market research studies are complex and tend to use questionnaires and grading scales. We needed an approach that would rapidly provide us with the answer to a patient-focused question, one that is very important to their care. The data analysis and report provided by Prism and dMetrics substantiated what had previously been our clinical impression with objective data. There are many potential uses to which this research methodology could be applied.”
James Sawyer, CEO of Prism Ideas comments: “This application of research via social media to the pharmaceutical industry is completely unique and demonstrates our dedication to being at the forefront of innovation. By marrying our expertise with the language processing technology offered by dMetrics, we have successfully developed a powerful mechanism to provide meaningful patient insight data for healthcare providers and the pharmaceutical industry. This advance is very timely and in line with the increasing emphasis on the importance of patient perspective.”
Paul Nemirovsky, CEO of dMetrics comments: “Today, we have an unparalleled opportunity to directly understand patients, in their own unbiased words, through their decisions, online. Being able to eliminate the mystery of consumer decisions is key to understanding behaviour, pulling patients’ individual experiences into a universe of healthcare insights. Our algorithms enable us to pinpoint the relevant decisions within Big Data and identify decision trends. dMetrics’ computer-generated insights, combined with Prism’s expertise in the medical domain allow the healthcare industry to interrogate patient experience in a rapid, accurate, and unbiased manner. Our goal is to help the healthcare industry to optimise their product decisions to directly improve the lives of millions of patients.”
For further information about Prism Ideas, please call +44 (0) 1270 621 724 or visit www.prismideas.com
For further information about dMetrics, please email info@dmetrics.com or visit www.dmetrics.com
About Prism Ideas
Prism Ideas is an independent company providing drug development consultancy and expert medical affairs support to the pharmaceutical industry. The company offers a full range of medical communications services, drug development consultancy and expert medical support throughout the clinical evaluation of drugs from early stage clinical studies through to post-marketing activities.
Prism’s knowledge of industry, together with a thorough understanding of the science, ensures that clinical trials and medical communications maintain the highest scientific quality whilst meeting the needs of the pharmaceutical industry.
Prism currently has offices in the UK, Basel, Switzerland and Boston in the U.S.
About dMetrics
dMetrics harnesses the clutter of Big Data, identifying, within online chatter, everyday decisions made by millions of people. In healthcare, dMetrics’ algorithms utilise a custom deep parsing natural language processing technology to ‘read’ the motivations and perceptions that surround these decisions, translating online chatter into actionable insight about any given product. The industry use for dMetrics data includes brand positioning, targeting drug development, ad-spend optimisation, as well as strengthening regulatory and reimbursement dossiers.
By providing clear, relevant, and simple ways to analyse and dissect decisions, we aim to become the primary resource for crowd-sourced decision insights for people worldwide, in healthcare and beyond.
Headquartered in Cambridge MA, the company has offices in Barcelona and Tel Aviv, with plans to establish a NYC office in 2012.
For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: prism@scottpr.com
With increasing regulatory and healthcare provider interest in patient-reported outcomes, there is a growing need for technology that can measure and empirically substantiate the benefits to patients of new medical products. Unlike simple keyword-based market research systems, dMetrics’ MIT-founded technology harnesses Big Data to identify who makes decisions, what they decide and why those decisions are made regarding a product, connecting the multitude of voices into a compelling patient narrative. Together, Prism Ideas and dMetrics bring previously unavailable, unbiased insight and analysis of the collective action of many individual patients.
Fully compliant with industry standards of practice in both market research and pharmacovigilance, the reports can be used both for drug development planning and product assessment, providing information on disease epidemiology, symptoms and clinical outcomes, in addition to patient insight and value judgments. For sponsors requiring the rapid and efficient delivery of meaningful and longitudinal data, without the hurdle of long lead times or regulatory committees, this service is designed to provide the ideal solution and can be tailored to a sponsor’s specific requirements.
In a recent study, Prism Ideas and dMetrics designed a protocol and conducted an in silico study for Allergy Therapeutics to establish the level of symptom improvement considered to be meaningful by allergy sufferers. Previously there had been no clinical or regulatory consensus upon this subject, calling into question the value of some medications. Applying their experience and expertise, dMetrics and Prism Ideas were able to capture first person data reports relating to treatment intervention, symptoms impacted and/or outcomes-related sentiment. The results of the study were important, indicating that for many patients relief of even one hayfever symptom such as a blocked nose or sneezing was very important.
Dr Tom Holdich, Research and Development Director for Allergy Therapeutics explains: “Conventional clinical trials and patient market research studies are complex and tend to use questionnaires and grading scales. We needed an approach that would rapidly provide us with the answer to a patient-focused question, one that is very important to their care. The data analysis and report provided by Prism and dMetrics substantiated what had previously been our clinical impression with objective data. There are many potential uses to which this research methodology could be applied.”
James Sawyer, CEO of Prism Ideas comments: “This application of research via social media to the pharmaceutical industry is completely unique and demonstrates our dedication to being at the forefront of innovation. By marrying our expertise with the language processing technology offered by dMetrics, we have successfully developed a powerful mechanism to provide meaningful patient insight data for healthcare providers and the pharmaceutical industry. This advance is very timely and in line with the increasing emphasis on the importance of patient perspective.”
Paul Nemirovsky, CEO of dMetrics comments: “Today, we have an unparalleled opportunity to directly understand patients, in their own unbiased words, through their decisions, online. Being able to eliminate the mystery of consumer decisions is key to understanding behaviour, pulling patients’ individual experiences into a universe of healthcare insights. Our algorithms enable us to pinpoint the relevant decisions within Big Data and identify decision trends. dMetrics’ computer-generated insights, combined with Prism’s expertise in the medical domain allow the healthcare industry to interrogate patient experience in a rapid, accurate, and unbiased manner. Our goal is to help the healthcare industry to optimise their product decisions to directly improve the lives of millions of patients.”
For further information about Prism Ideas, please call +44 (0) 1270 621 724 or visit www.prismideas.com
For further information about dMetrics, please email info@dmetrics.com or visit www.dmetrics.com
About Prism Ideas
Prism Ideas is an independent company providing drug development consultancy and expert medical affairs support to the pharmaceutical industry. The company offers a full range of medical communications services, drug development consultancy and expert medical support throughout the clinical evaluation of drugs from early stage clinical studies through to post-marketing activities.
Prism’s knowledge of industry, together with a thorough understanding of the science, ensures that clinical trials and medical communications maintain the highest scientific quality whilst meeting the needs of the pharmaceutical industry.
Prism currently has offices in the UK, Basel, Switzerland and Boston in the U.S.
About dMetrics
dMetrics harnesses the clutter of Big Data, identifying, within online chatter, everyday decisions made by millions of people. In healthcare, dMetrics’ algorithms utilise a custom deep parsing natural language processing technology to ‘read’ the motivations and perceptions that surround these decisions, translating online chatter into actionable insight about any given product. The industry use for dMetrics data includes brand positioning, targeting drug development, ad-spend optimisation, as well as strengthening regulatory and reimbursement dossiers.
By providing clear, relevant, and simple ways to analyse and dissect decisions, we aim to become the primary resource for crowd-sourced decision insights for people worldwide, in healthcare and beyond.
Headquartered in Cambridge MA, the company has offices in Barcelona and Tel Aviv, with plans to establish a NYC office in 2012.
For further press information please contact: Michelle Valentine, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: prism@scottpr.com
PRECOS to Unveil New Pre-clinical Oncology Service Portfolio at the 2012 3rd Cancer Targets & Therapeutics Conference and AACR 2012
NOTTINGHAM, UK, 1st February 2012 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, will be showcasing several new platforms for pre-clinical oncology research at two leading shows: Cancer Targets & Therapeutics, Las Vegas, February 27th - 28th and AACR, Chicago, March 31st - April 4th 2012.
PRECOS leads the way in providing robust models, validated against today’s Standard Of Care agents to enable pre-clinical in vitro and in vivo testing of the next generation of oncology candidate drugs. The International Agency for Research on Cancer (IARC) forecasts that by 2030 there will be over 26 million new cases and 17 million deaths per year from cancer. PRECOS will be launching several new cutting-edge services at the North American shows which support target validation and drug screening early in the research process for anti-cancer activity. The company provides expertise, specialism and innovation to small to medium biotechnology companies and the new platforms will support new and existing projects going forward.
At the shows PRECOS will highlight how it can deliver a customised screening platform either in 2-D or 3-D in vitro and/or in vivo that can far more closely model the development of cancer and therefore more accurately reflect the effect of potential candidate entities. Cell lines created from patient primary tissue that “never see plastic” are selected based their true characteristics as cancer cells, instead of their ability to survive in vitro.
Dr Neil Rotherham, chairman of PRECOS comments, “The new service lines demonstrate our commitment to offer a world-class service and the platforms provide significant benefits to clients. We are excited to talk to existing and potential clients from around the world at these leading events to demonstrate the breadth of solutions we can offer them for their oncology research and development needs.”
The 2012 3rd Cancer Targets & Therapeutics Conference examines new and emerging targets and therapeutics in the area of cancer research. Speakers at the event provide case studies of emerging targets in order to address some of the issues surrounding target-based drug discovery and development. The AACR Annual Meeting will highlight the best and latest findings in all major areas of cancer research. PRECOS’ full service offering will be highlighted at Cancer Targets & Therapeutics 2012 and on booth #4306 at AACR 2012. For further information please call +44 (0)870 166 6234, email enquiries@precos.co.uk or visit www.precos.co.uk
###
About PRECOS Ltd
PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade. For further information: www.precos.co.uk
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: precos@scottpr.com
PRECOS leads the way in providing robust models, validated against today’s Standard Of Care agents to enable pre-clinical in vitro and in vivo testing of the next generation of oncology candidate drugs. The International Agency for Research on Cancer (IARC) forecasts that by 2030 there will be over 26 million new cases and 17 million deaths per year from cancer. PRECOS will be launching several new cutting-edge services at the North American shows which support target validation and drug screening early in the research process for anti-cancer activity. The company provides expertise, specialism and innovation to small to medium biotechnology companies and the new platforms will support new and existing projects going forward.
At the shows PRECOS will highlight how it can deliver a customised screening platform either in 2-D or 3-D in vitro and/or in vivo that can far more closely model the development of cancer and therefore more accurately reflect the effect of potential candidate entities. Cell lines created from patient primary tissue that “never see plastic” are selected based their true characteristics as cancer cells, instead of their ability to survive in vitro.
Dr Neil Rotherham, chairman of PRECOS comments, “The new service lines demonstrate our commitment to offer a world-class service and the platforms provide significant benefits to clients. We are excited to talk to existing and potential clients from around the world at these leading events to demonstrate the breadth of solutions we can offer them for their oncology research and development needs.”
The 2012 3rd Cancer Targets & Therapeutics Conference examines new and emerging targets and therapeutics in the area of cancer research. Speakers at the event provide case studies of emerging targets in order to address some of the issues surrounding target-based drug discovery and development. The AACR Annual Meeting will highlight the best and latest findings in all major areas of cancer research. PRECOS’ full service offering will be highlighted at Cancer Targets & Therapeutics 2012 and on booth #4306 at AACR 2012. For further information please call +44 (0)870 166 6234, email enquiries@precos.co.uk or visit www.precos.co.uk
###
About PRECOS Ltd
PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade. For further information: www.precos.co.uk
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: precos@scottpr.com
Wednesday 1 February 2012
Wyatt Technology Instruments Employed to Develop Alternative Materials to Faulty Silicone Breast Implants
(SANTA BARBARA, CALIFORNIA – February 01 2012) - Wyatt Technology Corporation, the world leader in absolute macromolecular characterization instrumentation and software, today announced that Professor Judit E. Puskas at the University of Akron has developed a system using its instrumentation that will also help to solve a prevalent and particularly controversial material science challenge. The researchers are employing the multi detector system to develop alternative materials to silicone breast implants. This development will be welcomed by many as faulty Poly Implant Prothèse (PIP) implants are causing global concern about implant safety, and as a result, alternative materials are sought.
The recent scandal concerning French-made PIP implants concerns thousands of women across 65 countries with 300,000 potentially harmful implants sold over the last 12 years. It was revealed that these implants contained industrial silicone, intended for use in mattresses, rather than medical-grade silicone fillers.
With The Debut of HSIR+, ZaagTech Realizes First 3D Curved Multi-touch Wall
(Amsterdam, The Netherlands, February 1st, 2012) ZaagTech, the leading multi-touch solutions provider, unveiled a customized multi-touch wall composed of multiple touch screens powered by HSIR+ (Hybrid Scattered Infrared Plus) technology at ISE 2012 (Integrated System Europe) held in Amsterdam, January 31st to February 2nd, 2012. Zaagtech demonstrated the benefits of the multi-touch wall’s 3D curved shape, which due to the company’s HSIR+ technology, is being realized for the first time.
HSIR+ represents the new generation of infrared technology which is able to transfer any symmetrical shape onto a multi-touch screen. “The revolutionary innovation that HSIR+ signifies is breaking the constraints of traditional infrared screens which are only available on one single plane. We are the only provider that can make such 3D multi-touch walls,” said Olivia Yin, Vice President, Sales & Marketing at ZaagTech, “The multi-plane touch screen seen at the show is the first step and we will soon demonstrate the first round shape touch screen to the world. Our proprietary HSIR+ technology brings electrifying value to interactive solutions.”
At ISE 2012, ZaagTech also showcased a customized multi-touch table which is three inches thick and supports up to 40 simultaneous touch points. This solution enables smooth multi-user interaction on any sized screen and is a ready-to-use product for commercial use. The multi-touch table is a powerful addition to ZaagTech’s current product portfolio of X Series and N Series, covering multi-touch overlays supporting various numbers of true touch points (2-40) across screens ranging from 32”-200”.
ISE 2012 is the largest professional AV and systems integration trade show held in Europe, bringing together manufacturers, distributors, integrators and technology managers from over a hundred countries worldwide.
# # #
About ZaagTech
ZaagTech was founded in May 2010 by a team of engineers from Silicon Valley and an MBA from Harvard Business Scool. The company now has 15 patents, 40 engineers, three offices and two production lines. The firm has developed strategic collaboration with China Unicom, LG, Samsung, Mercedes-Benz, etc., and has received multiple governmental awards. ZaagTech has become a recognized brand for product innovation, commitment to quality and technical leadership in the field.
“Touching Life, Connecting More”. ZaagTech’s mission is to create high-end multi-touch products for use at home and office at the most affordable prices. The team members are enthusiastic in research, development, and production in the multi-touch market and the firm achieves results with products that use visually rich, intuitive, and powerful techniques. For more information, please visit www.zaagtech.com
HSIR+ represents the new generation of infrared technology which is able to transfer any symmetrical shape onto a multi-touch screen. “The revolutionary innovation that HSIR+ signifies is breaking the constraints of traditional infrared screens which are only available on one single plane. We are the only provider that can make such 3D multi-touch walls,” said Olivia Yin, Vice President, Sales & Marketing at ZaagTech, “The multi-plane touch screen seen at the show is the first step and we will soon demonstrate the first round shape touch screen to the world. Our proprietary HSIR+ technology brings electrifying value to interactive solutions.”
At ISE 2012, ZaagTech also showcased a customized multi-touch table which is three inches thick and supports up to 40 simultaneous touch points. This solution enables smooth multi-user interaction on any sized screen and is a ready-to-use product for commercial use. The multi-touch table is a powerful addition to ZaagTech’s current product portfolio of X Series and N Series, covering multi-touch overlays supporting various numbers of true touch points (2-40) across screens ranging from 32”-200”.
ISE 2012 is the largest professional AV and systems integration trade show held in Europe, bringing together manufacturers, distributors, integrators and technology managers from over a hundred countries worldwide.
# # #
About ZaagTech
ZaagTech was founded in May 2010 by a team of engineers from Silicon Valley and an MBA from Harvard Business Scool. The company now has 15 patents, 40 engineers, three offices and two production lines. The firm has developed strategic collaboration with China Unicom, LG, Samsung, Mercedes-Benz, etc., and has received multiple governmental awards. ZaagTech has become a recognized brand for product innovation, commitment to quality and technical leadership in the field.
“Touching Life, Connecting More”. ZaagTech’s mission is to create high-end multi-touch products for use at home and office at the most affordable prices. The team members are enthusiastic in research, development, and production in the multi-touch market and the firm achieves results with products that use visually rich, intuitive, and powerful techniques. For more information, please visit www.zaagtech.com
Subscribe to:
Posts (Atom)